Emicizumab
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche).
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). Emicizumab is a bispecific factor IXa- and factor X-directed antibody.
Emicizumab was first approved by the U.S. Food and Drug Administration (FDA) in November 2017 for routine prophylaxis in patients with hemophilia A who have developed factor VIII inhibitors. In October 2018, the FDA expanded approval, under the breakthrough therapy designation, to include all patients with hemophilia A, regardless of inhibitor status.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines.
Adverse effects
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
HAVEN clinical trial program
Emicizumab was evaluated in one of the largest pivotal clinical trial programs in hemophilia A, comprising four pivotal Phase III studies known as the HAVEN trials.
HAVEN 1 study
HAVEN 1 was a randomized, multicenter, open-label Phase III trial that included 109 male patients (ages 12–75 years) with severe hemophilia A and factor VIII inhibitors. The study demonstrated that emicizumab prophylaxis significantly reduced bleeding episodes compared to no prophylaxis in patients with inhibitors.
HAVEN 3 study
HAVEN 3 evaluated emicizumab in patients with severe hemophilia A without factor VIII inhibitors. The trial demonstrated that subcutaneous emicizumab prophylaxis, administered either once weekly or every two weeks, resulted in bleeding rates that were significantly lower by more than 95% compared to no prophylaxis. More than 55% of participants in each randomized emicizumab regimen experienced no treated bleeds during the study period.
Additional HAVEN studies
The clinical program also included HAVEN 2 (pediatric patients with inhibitors) and HAVEN 4 (patients switching from bypassing agent prophylaxis), further establishing the efficacy and safety profile of emicizumab across different patient populations.
Regulatory approvals
Emicizumab received its first regulatory approval from the FDA on November 16, 2017, under the brand name Hemlibra for routine prophylaxis in adult and pediatric patients with hemophilia A who have developed factor VIII inhibitors. This approval was based on results from the HAVEN 1 and HAVEN 2 clinical trials.
On October 4, 2018, the FDA expanded the approval under the Breakthrough Therapy designation to include all adult and pediatric patients (newborn and older) with hemophilia A, regardless of inhibitor status. This expanded approval was based on data from the HAVEN 3 and HAVEN 4 studies.
Emicizumab has since received regulatory approvals in numerous countries worldwide, including approval by the European Medicines Agency (EMA) and other international regulatory authorities.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371816961 under CC BY-SA 4.0; modifications have been made.